Asset | Description | Preclinical | Phase 1 | Phase 2 | Phase 3 | Status |
---|---|---|---|---|---|---|
Products |
||||||
ISB 1342 |
![]() CD38 x CD3
BEAT® 1.0
bispecific antibody
|
Phase 1 Orphan Drug | ||||
ISB 1442 |
![]() CD38 x CD47 BEAT® 2.0
bispecific antibody
|
PHASE 1 Orphan Drug | ||||
ISB 2001 |
![]() BCMA x CD38 x CD3 TREAT™ trispecific antibody
|
PHASE 1 Orphan Drug | ||||
Candidates |
||||||
ISB 2301 |
NK-cell engaging
multispecific platform
|
Discovery |
Products
Candidates
*Will be advanced with a partner
BEAT®: Bispecific Engagement by Antibodies based on the TCR
TREAT™: Trispecific Engagement by Antibodies based on the TCR
Products | Description | Preclinical | Phase 1 | Phase 2 | Phase 3 | Status |
---|---|---|---|---|---|---|
ISB 830 (telazorlimab) (Licensed to Astria Therapeutics) |
OX40 antagonist monoclonal antibody
|
Phase 2b completed†![]() |
||||
ISB 880 / ALM27134 (Licensed to Almirall S.A.) |
IL-1RAP antagonist monoclonal antibody
|
Phase 1![]() |
*A US IND for rheumatoid arthritis and other autoimmune indications is active.
†Primary efficacy endpoint (EASI score, % change, baseline to week 16) met at two highest doses tested. Numerical improvements were seen for the two higher-dose arms (300 mg and 600 mg q 2 weeks) of telazorlimab compared to placebo in the secondary endpoints of EASI-75 and Investigator Global Assessment, but the differences were generally not statistically significantly different from placebo.
The link above is provided for your convenience, and Ichnos is not responsible for content, privacy, or security issues associated with your visit to external websites.